If you're having trouble viewing this email, see it on the Web.
Technet21

Home | Invite Others | Digest Archives  
Posts:

technet21 postspacerOn the Importance of Programme Support To EPI Logistics

technet21 postspacerChallenges and Opportunities of Using Vaccines Out of the 2-8°C Range

technet21 postspacerVPPAG–gPPP for New Vaccines: Ver 2.1
Issue 19, 7 September 2009

 
Editorial Note

The response to Michel Zaffran's post on selecting a term for ‘storing and transporting vaccines outside of the 2-8°C range’ has been quite overwhelming. Thank you for your participation. Those of you who have been a little late in accessing this note and would like to contribute to the discussion, please click here. As an offshoot of this post, two new related topics have come up for discussion, one on programme support and the other on the challenges and opportunities of introducing these vaccines.

Simona Zipursky shares the latest VPPAG paper on generic Preferred Product Profile for new vaccines for public sector use in developing countries.


 by Jules Millogo

... However, weak vaccination coverage should not be blamed on logistics, logisticians and the very universal excuse of “lack of resources”.

   • Some populations live across the street of health centers and are not vaccinated.

   • Some people are afraid of vaccinations for various reasons (rational or irrational).

   • Some districts or countries still report more than 100% of coverage.

   • Costly disease surveillance systems still fail to detect outbreaks until it is too
      late to contain them, etc.

[Read more]

Comment on this post by email or on the web

 by C Nagaraj

The issues are to be looked at differently. The longevity of the thermostable vaccine v⁄s routine vaccines that can survive higher temperatures and being effective for say 30 days ...

[Read more]

Comment on this post by email or on the web

 by Simona Zipursky

Following a month long public consultation process, the Vaccine Presentation and Packaging Advisory Group (VPPAG) has released version 2.1 of the Generic Preferred Product Profile (gPPP). This version incorporates all comments received to date from a wide range of partners and stakeholders, including industry, NGOs, UN agencies and public health experts.

[Read more]

Comment on this post by email or on the web
Refrigerator
Photo Courtesy: Ranjit Dhiman
  
Immunization
Photo Courtesy: Ranjit Dhiman

  Web Highlights:
  technet21 post WHO supports fair access to influenza A (H1N1) vaccine: An interview with Marie–Paule Kieny
  technet21 post Laboratory Surveillance for Wild and Vaccine–Derived Polioviruses—Worldwide, January 2008–June 2009
  technet21 post Phase 3 malaria vaccine trial begins—final testing of RTS,S
  technet21 post Mobile Phone Based Clinical Microscopy for Global Health Applications

 



Register

 

If you have contributions to make or thoughts to share with others on TechNet21, you can write to the moderator or post directly on the web forums. Click here to change your subscription settings or unsubscribe from the mailing list.

TechNet21 is generously supported by the Bill and Melinda Gates Foundation, under the oversight of WHO and UNICEF. The information in this forum is provided by users, as a service. All contributions are reviewed prior to posting, and all postings are attributed to the authors. The details given in emails will not be voluntarily shared or sold to any outside company and will only be used for verification and to identify postings, if necessary. The authors are solely responsible for their submissions, and the readers are solely responsible for the interpretation of these submissions. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to this forum.

For posts where the author is a WHO staff member, the author alone is reponsible for the views expressed and they do not necessarily represent the decisions, guidelines, recommendations or policies of WHO.